Kurs
-1,39%
Likviditet
8,17 MNOK
Kalender
Est. tid* | ||
2025-08-29 | 07:00 | Kvartalsrapport 2025-Q2 |
2025-04-25 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2025-04-24 | - | Årsstämma |
2025-02-26 | - | Bokslutskommuniké 2024 |
2025-01-06 | - | Extra Bolagsstämma 2025 |
2024-08-30 | - | Kvartalsrapport 2024-Q2 |
2024-04-12 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2024-04-11 | - | Årsstämma |
2024-02-28 | - | Bokslutskommuniké 2023 |
2023-08-31 | - | Kvartalsrapport 2023-Q2 |
2023-04-27 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2023-04-26 | - | Årsstämma |
2023-02-28 | - | Bokslutskommuniké 2022 |
2022-08-31 | - | Kvartalsrapport 2022-Q2 |
2022-04-29 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2022-04-28 | - | Årsstämma |
2022-03-01 | - | Bokslutskommuniké 2021 |
2021-11-18 | - | 15-10 2021-Q3 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-05-26 | - | Kvartalsrapport 2021-Q1 |
2021-04-28 | - | Årsstämma |
2021-04-16 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2021-03-22 | - | Extra Bolagsstämma 2021 |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-11-19 | - | Kvartalsrapport 2020-Q3 |
2020-10-21 | - | Extra Bolagsstämma 2020 |
2020-08-27 | - | Kvartalsrapport 2020-Q2 |
2020-06-11 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2020-06-10 | - | Årsstämma |
2020-05-26 | - | Kvartalsrapport 2020-Q1 |
2020-02-27 | - | Bokslutskommuniké 2019 |
2019-11-19 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-23 | - | Kvartalsrapport 2019-Q1 |
2019-04-26 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2019-04-25 | - | Årsstämma |
2019-02-18 | - | Extra Bolagsstämma 2019 |
2018-08-22 | - | Kvartalsrapport 2018-Q2 |
2018-05-31 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2018-05-30 | - | Årsstämma |
2018-05-30 | - | Kvartalsrapport 2018-Q1 |
2018-02-27 | - | Bokslutskommuniké 2017 |
2017-12-20 | - | Extra Bolagsstämma 2017 |
2017-11-22 | - | Kvartalsrapport 2017-Q3 |
2017-08-23 | - | Kvartalsrapport 2017-Q2 |
2017-05-26 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2017-05-24 | - | Årsstämma |
2017-05-24 | - | Kvartalsrapport 2017-Q1 |
2017-02-28 | - | Bokslutskommuniké 2016 |
2016-11-23 | - | Kvartalsrapport 2016-Q3 |
2016-10-12 | - | Extra Bolagsstämma 2016 |
2016-08-24 | - | Kvartalsrapport 2016-Q2 |
2016-05-31 | - | Kapitalmarknadsdag 2016 |
2016-05-20 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2016-05-19 | - | Årsstämma |
2016-05-19 | - | Kvartalsrapport 2016-Q1 |
2016-02-26 | - | Bokslutskommuniké 2015 |
2015-11-17 | - | Kapitalmarknadsdag 2015 |
2015-10-21 | - | Kvartalsrapport 2015-Q3 |
2015-08-26 | - | Kvartalsrapport 2015-Q2 |
2015-05-27 | - | Kvartalsrapport 2015-Q1 |
2015-03-09 | - | Årsstämma |
2014-11-12 | - | Extra Bolagsstämma 2014 |
Beskrivning
Land | Norge |
---|---|
Lista | Oslo Bors |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
Oslo, Norway, 7 April 2021
Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 28 April 2021, at 14:00 hours CEST at Kjelsåsveien 168 B 0884 Oslo. The full notice with appendices and the recommendation from the Nomination Committee are attached. The notice and the documents to which it refers are also available on www.nordicnanovector.com.
Shareholders wishing to attend the Annual General Meeting, in person or by proxy, must complete and return the attendance form or power of attorney form attached to the notice to Nordea Bank Abp, Issuer Service, Postboks 1166 Sentrum, N-0107 Oslo, or by email to nis@nordea.comno later than 26 April 2021, 16:00 CEST. Attendance or proxies may also be registered electronically through VPS Investor Services.
For further information, please contact:
IR enquiries
Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.
Further information can be found at www.nordicnanovector.com.